



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/790,182	03/02/2004	Saul Yedgar	P-2507-US2	3956

27130 7590 01/13/2006

BITAN, PEARL, LATZER & COHEN ZEDEK LLP
10 ROCKEFELLER PLAZA, SUITE 1001
NEW YORK, NY 10020

EXAMINER


O SULLIVAN, PETER G

ART UNIT

PAPER NUMBER

1621

DATE MAILED: 01/13/2006



Please find below and/or attached an Office communication concerning this application or proceeding


ATTORNEY: RTB

ACTION: D-0A DUE: 13 Apr 06

ACTION: _____ DUE: _____

ACTION: _____ DUE: _____

DOCKETED BY: JP DATE: 23/1/06



Office Action Summary

Application No.	Applicant(s)	
10/790,182	YEDGAR ET AL	
Examiner	Art Unit	
Peter G. O'Sullivan	1621	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a) In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133) Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 November 2005.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-21 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a)
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d)
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Claims 1-21 are pending in this application which should be reviewed for errors. In response to the requirement for the election of a single disclosed species, applicants elected phosphatidylethanolamine bound to glycosaminoglycans. All other compounds and methods are held withdrawn from consideration.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention

Claims 8-14 provides for the use of applicants' compounds, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 8-14 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States

Claims 15-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Aoki et al., US 5,470,578, who disclose anticipating chondroitin and hyaluronic acid derivatives in the examples.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teaching of Yedgar et al., US 5,064,817, Chaikof et al., US 6,171,614, and Aoki et al., US 5,470,578, in view of Pruzanski et al., US 6,043,231, Sorgente et al., US 6,162,787, and Falk et al., US 6,022,866. Yedgar et al. disclose anti-inflammatory derivatives including distearoyl phosphatidylethanolamines covalently bonded through the amine group to carrier moieties which may include polysaccharides (s. Col. 2, ll. 50-58 and Col. 4, ll. 43-59). Yedgar et al. disclose their compounds to be PLA2 inhibitors,

thus having utility in a wide variety of oversecretory disease states such as allergic response, inflammation, atherosclerosis, thrombosis, etc. (Col. 13, top and middle). Although chondroitin and hyaluronic acid are not specifically mentioned by Yedgar et al. as carrier moieties, their listing is clearly not meant to be exhaustive. Chondroitin sulfate and hyaluronic acid are polysaccharides. Chaikof et al. disclose targeting of therapeutic agents using glycophospholipids generically overlapping applicants' (s. Col. 3, bottom). Chaikof et al. disclose the saccharide derivative used in the glycophospholipid may itself be therapeutic and specifically mentions chondroitin sulfate (s. Col. 5, second and third paragraphs). Aoiki et al., disclose antirheumatic compositions generically overlapping applicants' with anticipating examples (s. examples).

The instant invention differs from the teaching of the cited references in that applicants' activity against intestinal diseases is not specifically disclosed and in that other compounds are claimed which are not specifically exemplified. Pruzanski et al. is relied on to teach PLA2 inhibiting compounds to be useful in treating inflammatory bowel diseases and various inflammatory disorders. Sorgente et al. disclose chondroitin sulfate to be useful as an anti-inflammatory. Falk et al. is relied on to teach hyaluronic acid itself to be useful in the atherosclerotic process of restinosis. Especially in view of the teaching of Chaikof et al. that the saccharide derivative itself may be therapeutic, it would have been prima facie obvious at the time the invention was made to start with the teaching of the cited references, to make applicants' compounds and to expect to produce compound and compositions useful as anti-inflammatory agents or

Art Unit: 1621

agents in the treatment of disease states such as atherosclerosis, inflammatory bowel diseases, etc. To make further compounds generically disclosed, but not specifically exemplified would be further prima facie obvious in view of close or anticipating compounds already made.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 15-21 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over the claims of copending Application No. 09/756,765. Although the conflicting claims are not identical, they are not patentably distinct from each other because applicants' compositions would be obvious over their compounds.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

p. 3501-05


Application/Control Number: 10/790,182
Art Unit: 1621

Page 6


No claim is allowed.

Any inquiry concerning this communication should be directed to Peter G.

O'Sullivan at telephone number (571)272-0642.


PETER O'SULLIVAN
PRIMARY EXAMINER
(571) 272-0642

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/790,182
		Filing Date	March 2, 2004
		First Named Inventor	YEDGAR, Saul
		Group Art Unit	1621
		Examiner Name	O'Sullivan, Peter G
(use as many sheets as necessary)		Attorney Docket Number	P-2507-US2
Sheet	2	of	3


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
1/10	N	ALBINI, A. IWAMOTO, Y. KLEINMAN, H.K. MARTIN, GR. AARONSON, SA, KOZLOWSKI, JM AND MCEWAN, RN (1987) "A rapid in vitro assay for quantitating the invasive potential of tumor cells" <u>Cancer Res</u> 47(12):3239-45	<input type="checkbox"/>
↑	O	BALSINDE, J, BALBOA, MA. YEDGAR, S AND DENNIS, EA (2000) "Group V phospholipase A(2)-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D(1) macrophages" <u>J Biol Chem</u> 275(7):4783-6	<input type="checkbox"/>
	P	BECK, G, YARD, BA, SCHULTE, J. OBERACKER, R. VAN ACKERN, K, VAN DER WOUDE, F.J, KRIMSKY, M, KASZKIN, M AND YEDGAR, S (2002) "Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane" <u>Br J Pharmacol</u> 135(7):1665-74	<input type="checkbox"/>
	Q	CABANAS, C AND HOGG, N (1993) "Ligand intercellular adhesion molecule 1 has a necessary role in activation of integrin lymphocyte function-associated molecule 1" <u>Proc Natl Acad Sci U S A</u> 90(12):5838-42	<input type="checkbox"/>
	R	CHEN, WM, SORIA, J, SORIA, C, KRIMSKY, M AND YEDGAR, S (2002) "Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A(2)" <u>FEBS Lett</u> 522(1-3):113-8	<input type="checkbox"/>
	S	DAN, P, DAGAN, A, KRIMSKY, M, PRUZANSKI, W, VADAS, P AND YEDGAR, S (1998) "Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers" <u>Biochemistry</u> 37(17):6199-204	<input type="checkbox"/>
	T	GREAVES MW AND CAMP RD (1988) "Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin" <u>Arch Dermatol Res</u> 280:S33-41	<input type="checkbox"/>
	U	KRIMSKY, M, DAGAN, A, APTEKAR, L, LIGUMSKY, M AND YEDGAR, S (2000) "Assessment of intestinal permeability in rats by permeation of inulin-fluorescein" <u>J Basic Clin Physiol Pharmacol</u> 11(2):143-53	<input type="checkbox"/>
	V	KRIMSKY, M, YEDGAR, S, APTEKAR, L, SCHWOB, O, GOSHEN, G, GRUZMAN, A, SASSON, S AND LIGUMSKY, M (2003) "Amelioration of TNBS-induced colon inflammation in rats by phospholipase A2 inhibitor" <u>Am J Physiol Gastrointest Liver Physiol</u> 285(3):G586-92	<input type="checkbox"/>
	W	MARGOLIS-NUNNO, H, BEN-HUR, E, GOTTLIEB, P, ROBINSON, R, OETJEN, J AND HOROWITZ, B (1996) "Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates" <u>Transfusion</u> 36(8):743-50	<input type="checkbox"/>
↓	X	MURTHY, SN, COOPER, HS, SHIM, H, SHAH, RS, IBRAHIM, SA AND SEDERGRAN, DJ (1993) "Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin" <u>Dig Dis Sci</u> 38(9):1722-34	<input type="checkbox"/>
1/10	Y	OKAYASU, I, HATAKEYAMA, S, YAMADA, M, OHKUSA, T, INAGAKI, Y AND NAKAYA, R (1990) "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice" <u>Gastroenterology</u> 98(3):694-702	<input type="checkbox"/>

Examiner Signature	<i>P. O'Sullivan</i>	Date Considered	Jan 2006
--------------------	----------------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached

Please type a plus sign (+) inside this box →



Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/790,182
		Filing Date	March 2, 2004
		First Named Inventor	YEDGAR, Saul
		Group Art Unit	1621
(use as many sheets as necessary)		Examiner Name	O'Sullivan, Peter G
Sheet	3 of 3	Attorney Docket Number	P-2507-US2

Examiner Signature	Date Considered
--------------------	-----------------


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
1/15	Z	SCHMIEL, DH AND MILLER, VL (1999) "Bacterial phospholipases and pathogenesis" <u>Microbes Infect</u> 1(13):1103-12	<input type="checkbox"/>
1/15	AA	SCHNITZER, E, DAGAN, A, KRIMSKY, M, LICHTENBERG, D, PINCHUK, I, SHINAR, H AND YEDGAR, S (2000) "Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lipids to oxidation" <u>Chem Phys Lipids</u> 104(2):149-60	<input type="checkbox"/>
1/15	BB	SCHNITZER, E, PINCHUK, I, FAINARU, M, LICHTENBERG, D AND YEDGAR, S (1998) "LDL-associated phospholipase A does not protect LDL against lipid peroxidation in vitro" <u>Free Radic Biol Med</u> 24(7-8):1294-303	<input type="checkbox"/>
1/15	CC	SCHNITZER, E, YEDGAR, S, DANINO, D, TALMON, Y AND LICHTENBERG, D (1999) "The interaction of hyaluronic-phosphatidylethanolamine with low density lipoprotein (LDL) and its effect on copper induced LDL oxidation" <u>Biophysical Journal</u> 76(1): Part 2	<input type="checkbox"/>
1/15	DD	YARD, BA, YEDGAR, S, SCHEELE, M, VAN DER WOUDE, D, BECK, G, HEIDRICH, B, KRIMSKY, M, VAN DER WOUDE, FJ AND POST, S (2002) "Modulation of IFN-gamma-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid" <u>Transplantation</u> 73(6):984-92	<input type="checkbox"/>
1/15	EE	YEDGAR, S, LICHTENBERG, D AND SCHNITZER, E (2000) "Inhibition of phospholipase A(2) as a therapeutic target" <u>Biochim Biophys Acta</u> 1488(1-2):182-7	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1985, no persons are required to respon



Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	91397
				Filing Date	August 23, 1988
				First Named Inventor	
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	P-57917-IL

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>M. J. A.</i>	Date Considered	<i>Jan 2006</i>
-----------------------	-----------------	--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	91397
		Filing Date	August 23, 1989
		First Named Inventor	
		Group Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	P-57917-IL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<div style="display: flex; align-items: center; justify-content: center;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-size: 2em; margin-right: 10px;">↑</div> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-size: 2em; margin-right: 10px;">↓</div> </div>	D	Group V Phospholipase A ₂ -mediated Oleic Acid Mobilization in Lipopolysaccharide-stimulated P388D ₁ Macrophages; BALSINDE Jesus, BALBOA Maria A., YEDGAR Saul, and DENNIS Edward A., The Journal of Biological Chemistry, Vol 275, Feb 18 pp4783-4786	<input type="checkbox"/>
	E	Inhibition of LPS-induced chemokine production in human lung endothelial cells by lipid conjugates anchored to the membrane BECK, G. Ch, YARD B.A. SCHULTE J., OBERACKER. R, VAN ACKERN K, VAN DER WOUDE F.J, KRIMSKY M, KASZKIN M and YEDGAR Y.; British Journal of Pharmacology (2002) 135, 1685-1674	<input type="checkbox"/>
	F	Control of capillary formation by membrane-anchored extracellular inhibitor of phospholipase A ₂ ; CHEM, W.M, SORIA J, CORIA C, KRIMSKY M and YEDGAR S.; FEBS 26215 letters 522 (2002) 113-118	<input type="checkbox"/>
	G	Interaction of hyaluronic acid-linked phosphatidylethanolamine (HyPE) with LDL and its effect on the susceptibility of LDL lip to oxidation; SCHNITZER Edit, DAGAN Arie, KRIMSKY Miron, LICHTENBERG Dov, PINCHUK Ilya, SHINAR Hadassa, YEDGAR Saul; CPL 104 (2000) 149-160	<input type="checkbox"/>
	H	Inhibition of phospholipase A ₂ as a therapeutic target; YEDGAR Saul, LICHTENBERG Dov, SCHNITZER Edit, BBA Biochimica et Biophysica Acta 1488 (2000) 182-187	<input type="checkbox"/>
	I	Modulation of IFN-GAMMA-induced immunogenicity by phosphatidylethanolamine-linked hyaluronic acid; YARD Benito A., YEDGAR Saul, SCHEELE Martin, VAN DER WOULD DE Diane, BECK Grietje, HEIDRICH Barbel, KRIMSKY Miron, VAN DER WOULD DE Fokko J, and POST Stefan TRANSPLANTATION Vol 73, 984-992, No. 6, March 27, 2002	<input type="checkbox"/>
J	Inhibition of Type I and Type II Phospholipase A ₂ by Phosphatidyl-Ethanolamine Linked to Polymeric Carriers; PHYLLIS Dan, ARIE Dagan, MIRON Krinsky, WALDEMAR Pruzanski, PETER Vadas, and Saul Yedgar. Biochemistry 1998, 37, 6199-6204	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.